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Multiple Myeloma
Joan Bladé, Benedetto Bruno, 
and Mohamad Mohty
80.1  Definition, Epidemiology, 
and Diagnosis
Multiple myeloma (MM) consists of a malignant 
proliferation of BM plasmatic cells (BMPCs), 
which produce a monoclonal protein that can be 
found in serum and/or urine, resulting in skeletal 
involvement, hypercalcemia, anemia, renal func-
tion impairment, and/or soft-tissue plasmacyto-
mas. The cause is unknown.
The annual incidence is four per 100,000. It 
represents 1% of all malignant diseases and about 
15% of all hematological malignancies. The 
median age at diagnosis is between 65 and 
70 years. Only 15% and 2% are younger than 50 
and 30 years, respectively.
The diagnosis of symptomatic MM requires 
the presence of clonal BMPCs, usually >10%, or 
plasmacytoma, the presence of serum and/or 
urine M-protein (except in the uncommon nonse-
cretory) and related organ or tissue impairment 
(end-organ damage, including bone lesions). In 
the absence of organ damage, the presence of 
>60% BMPCs, a serum-free light-chain (FLC) 
ratio >100 or the presence of more than one focal 
lesion at the MRI defines symptomatic MM 
requiring therapy.
80.2  Risk Stratification
The International Staging System (ISS), based on 
the serum beta2-microglobulin and albumin lev-
els discriminates three prognostics subgroups:
• Stage I (beta2-m <3.5  mg/L and albumin 
>3.3 g/dL),
• Stage III (beta2-m >5.5 mg/L) and
• Stage II (all remaining cases).
FISH can identify the following poor cytoge-
netic findings: t(4;14), t(14;16), and/or del 17p 
which account for about 25% of patients with 
MM, the remaining 75% having a so-called stan-
dard risk. High LDH, the presence of hematoge-
nous extramedullary disease, and the coexistence 
of plasma cell leukemia are also poor prognostic 
indicators. A revised ISS incorporating cytoge-
netics and LDH have been developed as follows:
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• R-ISS I: ISS I, standard-risk cytogenetics and 
normal LDH,
• R-ISS III: ISS III, plus high-risk cytogenetics 
or high LDH and
• R-ISS II: all remaining cases.
An ultra-high-risk group, accounting for 5–7% 
of patients eligible for auto-HSCT and who received 
bortezomib-based regimens, with a median OS of 
less than 2 years, has been recognized (ISS III and 
high-risk cytogenetics or high LDH).
80.3  First-Line Treatment 
(Induction Prior 
to Auto-HSCT)
Conventional chemotherapy (VAD, VBMCP/
VBAD, CY/DEX) or the doublets thalidomide 
(THAL)/DEX or bortezomib (BOR)/DEX results 
in 10% CR pre-auto-HSCT, 25–35% CR post- 
auto- HSCT and in 5–10% in continued CR 
beyond 10 years from HSCT.
The triplets combining BOR/DEX with an 
immunomodulatory drug (IMiD), thalidomide 
(VTD), or lenalidomide (VRD) result in a pre- 
auto- HSCT CR of 20–35%, and a post-auto- HSCT 
CR of 45–55%. However, there is not enough fol-
low-up to determine the proportion of patients in 
continued CR >10 years beyond auto-HSCT.
The results of BOR-based triplets PAD and 
VCD (including Adriamycin or CY), widely used 
in Europe, are inferior to the reported with the 
combination of proteasome inhibitors plus 
IMiDs. Although most groups administer four 
induction cycles, the dose intensity and the induc-
tion exposure with an increased depth of response 
overtime and with higher CR rates pre- and post- 
auto- HSCT with six cycles have been observed 
with both VTD and VRD. The potential benefit of 
adding a MoAb, particularly daratumumab, to 
VTD or VRD is being investigated.
80.4  Criteria of Response 
and Progression
Complete remission (CR): negative serum and 
urine immunofixation, less than 5% BMPCs and 
no soft-tissue plasmacytomas.
Stringent CR: as above plus normal free light- 
chain ratio and absence of clonal plasma cells.
Very good partial response (VGPR): 90% or 
more decrease in the serum M-protein and urine 
M-protein <100 mg/24 h.
Partial response (PR): 50% or more decrease 
in the serum M-protein, 90% or more decrease in 
urine M-protein or to <200 mg/24 h plus 50% or 
more decrease in soft-tissue plasmacytomas.
Progressive disease (PD) requires one or more 
of the following: increase in 25% or more from 
nadir in serum M-protein (absolute increase of at 
least 0.5  g/dL), urine M-protein (absolute 
increase of at least 200 mg/24 h), BMPC (abso-
lute increase of at least 10%), soft-tissue plasma-
cytomas, and development of new bone lesions, 
soft-tissue plasmacytomas, or hypercalcemia.
80.5  High-Dose Therapy (HDT), 
Consolidation, 
and Maintenance
Auto-HSCT remains the standard of care for 
young and fit MM patients. MEL 200  mg/m2 
(MEL-200) is the standard high-dose regimen, 
and the source of PBS. The addition of BOR peri- 
transplant, as well as other attempts, is of no ben-
efit. MEL-140 plus IV BU vs. MEL-200 is being 
investigated. The increase in the CR with HDT is 
15–20%.
Recent trials have shown that early transplant 
is superior to delayed (at relapse) auto-HSCT, 
even in the era of novel agents.
It seems that patients with high-risk cytoge-
netics are the most likely to benefit from tandem 
auto-HSCT.
The TRM with auto-HSCT is very low (1–2%), 
the best reported median PFS is 50–56  months 
and the expected median OS of 8–10 years. The 
proportion of patients  operationally cured (i.e., in 
continued CR beyond 10 years) with the current 
regimens is still unknown.
Although the results of post transplant con-
solidation are controversial, it seems to be a 
promising approach and usually recommended 
by experts. Post-auto-HSCT maintenance with 
lenalinomide (LENA) has been recently 
approved. The optimal maintenance duration 
based on sequential MRD studies, as well as 
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whether or not the association of other drugs such 
as glucocorticoids, proteasome inhibitors or 
MoAb can be of benefit, is currently 
investigated.
80.6  Treatment at Relapse After 
Auto-HSCT
There is a consensus that a rescue or salvage 
auto-HSCT could be tried when the response 
duration to the first transplant in longer than 
18–24  months. Such rescue transplant should 
only be performed in patients with sensitive dis-
ease, so prior salvage chemotherapy is needed. 
The components of the initial therapy, depth and 
the duration of response as well as the toxicity 
are crucial in selecting the rescue regimen. 
Among a number of possible combinations at 
relapse, the more effective combinations are 
IMiD-containing (carfilzomib, LENA, and DEX 
[KRd] or daratumumab, LENA, and DEX [DRd]) 
and non-IMiD-containing (carfilzomib and DEX 
[Kd] or daratumumab, BOR and DEX [DVd]). If 
the rescue auto-HSCT is performed, post trans-
plant maintenance should be considered. In the 
event that the transplant is not done, the above 
treatments are in general until progression.
80.7  Allogenic HSCT in MM
The role of allografting for the treatment of MM 
remains controversial. The first clinical reports 
employing MAC regimens proved to be curative 
for small patient subsets but were associated with 
an unacceptable high TRM. In the late 1990s, the 
introduction of minimal intensive conditioning 
regimens (primarily based on low-dose TBI), 
which relies on the graft-versus-myeloma (GvM) 
effect for tumor eradication, drastically reduced 
TRM, but at the expense of higher disease 
relapse.
Combining cytoreductive high-dose MEL with 
an autograft and a subsequent minimal intensity 
conditioning with an allograft, aimed at inducing 
GvM, was better tolerated up to the age of 
65–70 years old. Before the era of new drugs, seven 
prospective trials were designed to compare clini-
cal outcomes of auto-HSCT versus tandem autolo-
gous-minimal intensity and allo-HSCT in newly 
diagnosed MM patients. Results were discordant 
regarding response, OS, and PFS. This may have 
partly been due to differences in conditioning regi-
mens, GVHD prophylaxis, patient inclusion crite-
ria, and randomization strategies. Thus, 
comparisons between trials are difficult. However, 
allografting has steadily been used in Europe in 
recent years. Sobh et al. recently described use and 
outcomes of allo- HSCT for MM in Europe between 
January 1990 and December 2012. A study popula-
tion of 7333 patients (median age at transplant, 
51  years) was divided into 3 groups: allo-HSCT 
upfront (n  =  1924), tandem auto-allo-HSCT 
(n = 2004), and allo-HSCT as a second-line treat-
ment or beyond (n = 3405). After 2004, 5-year sur-
vival probabilities from transplant were 42%, 54%, 
and 32%, for the three groups, respectively. 
Unfortunately, only a very minority of MM patients 
were enrolled in prospective control trials. 
Remarkable heterogeneity in using allo- HSCT was 
observed among the different European countries.
80.8  Allogenic HSCT and New 
Agents
The role of the combination of “new drugs” 
with GvM has not yet been explored in well-
designed prospective studies. In only a Phase II 
study feasibility of BOR within a RIC and as 
maintenance post-allografting was evaluated. 
Conditioning consisted of FLU/MEL/BOR 
while maintenance treatment of cycles of IV 
BOR.  Sixteen high-risk patients relapsed after 
an auto-HSCT was prospectively enrolled. 
Nine/16 (56%) and 5/16 (31%) achieved CR 
and partial remission. In this heavily pretreated 
high-risk population, 3-year cumulative inci-
dence of NRM, relapse and OS were 25%, 54%, 
and 41%, respectively. The latter trial showed 
the feasibility and efficacy of an intensified con-
ditioning with a “new drug” in poor prognosis 
patients. Moreover, the concept of maintenance 
treatment after an allograft was also introduced. 
A synergy between new drugs and GvM in the 
relapse setting has recently been described 
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clearly suggesting that allo-HSCT and new 
drugs are not mutually exclusive.
Whether long-term persistence of MRD nega-
tivity may coincide with disease eradication 
remains a matter of debate though persistent 
molecular remission of several years may cau-
tiously suggest cure. PCR-based MRD detection 
represents a powerful predictor of clinical 
outcomes.
80.9  Indications of allo-HSCT 
in MM
The role of allo-HSCT in the era of new drugs 
remains highly controversial, and there are no 
clear guidelines, despite the relatively high num-
bers of allo-HSCT yearly performed in Europe. 
Well-designed prospective trials combining 
“graft-vs.-myeloma” and new drugs are needed, 
especially in young high-risk/ultra-high-risk 
patients whose treatment remains an unmet clini-
cal need.
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